Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)

AtriCure (ATRC) reported $134.27 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 15.8%. EPS of -$0.01 for the same period compares to -$0.17 a year ago.

The reported revenue represents a surprise of +2.09% over the Zacks Consensus Estimate of $131.52 million. With the consensus EPS estimate being -$0.11, the EPS surprise was +90.91%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• United States Revenue- Pain management: $20.84 million versus the three-analyst average estimate of $20.59 million. The reported number represents a year-over-year change of +27.7%.
• International Revenue- Pain management: $2.08 million versus the three-analyst average estimate of $2.77 million. The reported number represents a year-over-year change of +30.8%.
• United States Revenue- Total ablation: $63.86 million compared to the $63.41 million average estimate based on three analysts. The reported number represents a change of +10.04% year over year.
• International Revenue- Total ablation: $14.79 million compared to the $14.54 million average estimate based on three analysts. The reported number represents a change of +24.52% year over year.
• United States Revenue- Total: $109.31 million versus $106.47 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.5% change.
• International Revenue- Appendage management: $10.17 million compared to the $10.58 million average estimate based on three analysts. The reported number represents a change of +18.5% year over year.
• United States Revenue- Open ablation: $35.59 million compared to the $34.88 million average estimate based on three analysts. The reported number represents a change of +16.3% year over year.
• International Revenue- Open ablation: $10.85 million compared to the $9.73 million average estimate based on three analysts. The reported number represents a change of +26.1% year over year.
• United States Revenue- Minimally invasive ablation: $7.43 million versus the three-analyst average estimate of $7.94 million. The reported number represents a year-over-year change of -33.2%.
• International Revenue- Minimally invasive ablation: $1.86 million versus $2.04 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
• United States Revenue- Appendage management: $45.45 million versus the three-analyst average estimate of $43.06 million. The reported number represents a year-over-year change of +21.5%.
• International Revenue- Total: $24.96 million versus $25.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22% change.

View all Key Company Metrics for AtriCure here>>>

Shares of AtriCure have returned -4.02% over the past month versus the Zacks S&P 500 composite's +0.95% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could perform in line with the broader market in the near term.

(We are reissuing this article to correct a mistake. The original article, issued on October 29, 2025, should no longer be relied upon.)

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Source Zacks-com